CAMBRIDGE, Mass., September 14, 2022 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. THIRD, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, today announced pricing for its increased initial public offering of 10,900,000 common shares at a public offering price of $17.00 per share . All shares are offered by Third Harmonic Bio. Gross proceeds from the Offering, before deducting underwriting rebates and commissions and other offering costs payable by Third Harmonic Bio, are expected to be $185.3 million. The shares are expected to start trading on the Nasdaq Global Market on September 15, 2022 under the ticker symbol “THRD”. The offering is expected to close on September 19, 2022, subject to the satisfaction of customary closing conditions. In addition, Third Harmonic Bio has granted the underwriters a 30-day option to purchase up to 1,635,000 additional common shares at the IPO price less subscription discounts and commissions.

Morgan Stanley, Jefferies and Cowen are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as co-manager for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and are effective on September 14, 2022. The offer is made only by means of a prospectus. A copy of the final prospectus, where available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY…